Tag Archives: PFE

Sangamo Therapeutics Stock History

If you’ve been following the news lately, you might have heard about gene editing, a process that involves rewriting a person’s DNA to correct genetic disorders, and you’re wondering what all the buzz is about.

While gene editing is getting a lot of attention recently, it’s far from a new idea. Sangamo Therapeutics (NASDAQ:SGMO) has been working on gene-editing research....More>>>

Sangamo Therapeutics Stock History

If you’ve been following the news lately, you might have heard about gene editing, a process that involves rewriting a person’s DNA to correct genetic disorders, and you’re wondering what all the buzz is about.

While gene editing is getting a lot of attention recently, it’s far from a new idea. Sangamo Therapeutics (NASDAQ:SGMO) has been working on gene-editing research....More>>>

Rounds Report: Solid Rallied While FDA Due Diligence To Help Branded Therapeutic Innovators

I cant give you a formulaic approach, because I dont use one. And I just mix all the factors and if the gap between value and price is not attractive, I go on to something else. And sometimes its just quantitative. For instance, when Costco was selling for 12 or 13 times earnings, I thought that was a ridiculously low value just because the competitive strength of the business was so great and it....More>>>

Are There Any Safe Stocks to Buy and Hold Anymore?

Conventional wisdom suggests that investors should find safe stocks to buy. Penny stocks and potential “triple-baggers” might be more exciting and a big win might provide a better story, but experts will tell you the smart play is to benefit from compounding returns in safe, stable stocks.

That general strategy is similar to that followed by Warren Buffett with Berkshire Hathaway....More>>>

Traders Sell Shares of Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer (NYSE:PFE) on strength during trading hours on Friday. $81.63 million flowed into the stock on the tick-up and $203.33 million flowed out of the stock on the tick-down, for a money net flow of $121.70 million out of the stock. Of all equities tracked, Pfizer had the 4th highest net out-flow for the day. Pfizer traded up $0.46 for the day and closed at $35.50

Several....More>>>

Roosevelt Investment Group Inc. Has $19.89 Million Holdings in Pfizer (PFE)

Roosevelt Investment Group Inc. grew its position in Pfizer (NYSE:PFE) by 14.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 549,252 shares of the biopharmaceutical company’s stock after purchasing an additional 68,162 shares during the quarter. Pfizer makes up approximately 1.8% of Roosevelt....More>>>

Sarepta Therapeutics: Backing A Cure For Duchenne Muscular Dystrophy

Succeeding 13 years of R&D with a commercial-level rare disease drug, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) tees up to deliver on the latter half of its promise to provide the world with a DMD cure for sufferers that may be amenable to Exon 51 skipping, and otherwise. A result that would facilitate the first cure for DMD and sizable growth potential.

In 2016, Sarepta Therapeutics,....More>>>

10 Biotech Stocks With Game-Changing Dates in Q3

For some investors, they’ve created small fortunes. For others, they’ve brought nothing but misery. For all investors, though, there’s no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn’t going to be any different.

To....More>>>

Vitality Biopharma Adds a Regulatory Heavyweight as an Advisor

The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval. 

That’s....More>>>

Why 3D Printing and Biotech Will Be Good Bets in 2017

Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.

Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products,....More>>>